Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Rhabdoid Tumor 1Papillary renal cell carcinoma, sporadic 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 11Specimen Handling 9Magnetic Resonance Spectroscopy 9pembrolizumab 6durvalumab 6Platinum 61,2-diaminocyclohexaneplatinum II citrate 6cemiplimab 5Carboplatin 5Radiation 4Cetuximab 4Biopsy 4poly ICLC 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Pemetrexed 3Paclitaxel 3Nivolumab 3Docetaxel 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cabozantinib 2atezolizumab 2Oxaliplatin 2Ipilimumab 2Immunoglobulin G 2Fluorouracil 2Disulfides 2Capecitabine 2ALT-803 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Erlotinib Hydrochloride × 30 days × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡